CN107208060B - 应用人脂肪衍生的干细胞增殖血清来源的丙肝病毒及其用途 - Google Patents

应用人脂肪衍生的干细胞增殖血清来源的丙肝病毒及其用途 Download PDF

Info

Publication number
CN107208060B
CN107208060B CN201580072851.XA CN201580072851A CN107208060B CN 107208060 B CN107208060 B CN 107208060B CN 201580072851 A CN201580072851 A CN 201580072851A CN 107208060 B CN107208060 B CN 107208060B
Authority
CN
China
Prior art keywords
hcv
cells
cell
virus
hadsc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580072851.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107208060A (zh
Inventor
林成龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WEISHI PHARMACEUTICAL (RUGAO) CO Ltd
Original Assignee
Vanworld Pharmaceutical Rugao Co Ltd
Frontier Bio-Drug Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanworld Pharmaceutical Rugao Co Ltd, Frontier Bio-Drug Development Ltd filed Critical Vanworld Pharmaceutical Rugao Co Ltd
Publication of CN107208060A publication Critical patent/CN107208060A/zh
Application granted granted Critical
Publication of CN107208060B publication Critical patent/CN107208060B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201580072851.XA 2015-01-07 2015-01-07 应用人脂肪衍生的干细胞增殖血清来源的丙肝病毒及其用途 Active CN107208060B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/070243 WO2016109947A1 (en) 2015-01-07 2015-01-07 Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof

Publications (2)

Publication Number Publication Date
CN107208060A CN107208060A (zh) 2017-09-26
CN107208060B true CN107208060B (zh) 2021-06-18

Family

ID=56355408

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580072851.XA Active CN107208060B (zh) 2015-01-07 2015-01-07 应用人脂肪衍生的干细胞增殖血清来源的丙肝病毒及其用途

Country Status (10)

Country Link
US (1) US10273461B2 (https=)
EP (1) EP3242932A4 (https=)
JP (1) JP6670322B2 (https=)
KR (1) KR20170101998A (https=)
CN (1) CN107208060B (https=)
AU (1) AU2015376561A1 (https=)
CA (1) CA2973119A1 (https=)
HK (1) HK1246824A1 (https=)
TW (1) TWI616528B (https=)
WO (1) WO2016109947A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272145A (en) * 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic compositions with protein concentrate from conditioned medium of adipose-derived stem cells
IL278473A (en) 2020-11-03 2022-06-01 Yeda Res & Dev Methods for diagnosing and determining treatment in multiple myeloma
CN114686517A (zh) * 2020-12-25 2022-07-01 中国医学科学院病原生物学研究所 一种hcv四受体转基因合并stat1敲除小鼠的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068557A1 (en) * 2011-11-09 2013-05-16 Katholieke Universiteit Leuven Virus infectable stem cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786207A (en) 1997-05-28 1998-07-28 University Of Pittsburgh Tissue dissociating system and method
CN1166773C (zh) 1997-12-02 2004-09-15 泽恩比奥公司 分离的人脂肪组织衍生的基质细胞
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20050076396A1 (en) 1999-03-10 2005-04-07 Katz Adam J. Adipose-derived stem cells and lattices
JP2009153383A (ja) * 2006-04-03 2009-07-16 Eci Inc 成熟肝細胞様細胞の製造方法
KR101224504B1 (ko) * 2010-10-01 2013-01-22 가톨릭대학교 산학협력단 크립토탄신온의 신규 용도
US20140179775A1 (en) * 2012-02-29 2014-06-26 Mead Johnson Nutrition Company Neurogenesis screening method and uses thereof
US9402710B2 (en) * 2012-07-16 2016-08-02 The Board Of Trustees For The Leland Stanford Junior University Macroporous 3-D scaffolds for tissue engineering

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013068557A1 (en) * 2011-11-09 2013-05-16 Katholieke Universiteit Leuven Virus infectable stem cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MicroRNA-27a Modulates HCV Infection in Differentiated Hepatocyte-Like Cells from Adipose Tissue-Derived Mesenchymal Stem Cells;Jung Eun Choi et al.,;《PLOS ONE》;20140513;第9卷(第5期);e91958 *
Proteomic analysis of primary cultures of human adipose-derived stem cells- Modulation by adipogenesis;Delany James P et al.,;《Proteomics》;20050630;第4卷(第6期);731-740 *

Also Published As

Publication number Publication date
EP3242932A1 (en) 2017-11-15
CN107208060A (zh) 2017-09-26
HK1246824A1 (zh) 2018-09-14
WO2016109947A1 (en) 2016-07-14
TW201625786A (zh) 2016-07-16
CA2973119A1 (en) 2016-07-14
AU2015376561A1 (en) 2017-07-27
KR20170101998A (ko) 2017-09-06
EP3242932A4 (en) 2018-05-30
US10273461B2 (en) 2019-04-30
JP6670322B2 (ja) 2020-03-18
TWI616528B (zh) 2018-03-01
JP2018501820A (ja) 2018-01-25
US20180023058A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
Roelandt et al. Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus
Yuan et al. A chimeric humanized mouse model by engrafting the human induced pluripotent stem cell-derived hepatocyte-like cell for the chronic hepatitis B virus infection
Kim et al. Development of hepatitis C virus genotype 3a cell culture system
CN102168065A (zh) 一种体外诱导人脐带间充质干细胞成为肝细胞的方法与应用
Li et al. LncRNA HULC promotes epithelial and smooth-muscle-like differentiation of adipose-derived stem cells by upregulation of BMP9
CN107208060B (zh) 应用人脂肪衍生的干细胞增殖血清来源的丙肝病毒及其用途
Guan et al. Caveolin-1 is essential in the differentiation of human adipose-derived stem cells into hepatocyte-like cells via an MAPK pathway-dependent mechanism
Nitta et al. Conversion of mesenchymal stem cells into a canine hepatocyte-like cells by Foxa1 and Hnf4a
Ma et al. Hepatitis B virus infection and replication in human bone marrow mesenchymal stem cells
Banaudha et al. Primary hepatocyte culture supports hepatitis C virus replication: a model for infection-associated hepatocarcinogenesis
Boyer et al. TM6SF2 promotes lipidation and secretion of hepatitis C virus in infected hepatocytes
Choi et al. MicroRNA-27a modulates HCV infection in differentiated hepatocyte-like cells from adipose tissue-derived mesenchymal stem cells
Kajimoto et al. Isolation and culture of microvascular endothelial cells from murine inguinal and epididymal adipose tissues
Lu et al. Tree shrew bone marrow–derived mesenchymal stem cells express CD81, OCLN, and miR‐122, facilitating the entire hepatitis C virus life cycle
CN103436555A (zh) 携带miR-122脂肪间充质干细胞的构建方法及其应用
WO2005024004A1 (ja) 間葉系幹細胞の肝細胞への分化方法及び人工ヒト肝臓細胞
Miyaji et al. Bone marrow-derived humoral factors suppress oxidative phosphorylation, upregulate TSG-6, and improve therapeutic effects on liver injury of mesenchymal stem cells
Aly et al. Strain-dependent viral dynamics and virus-cell interactions in a novelin vitrosystem supporting the life cycle of blood-borne hepatitis C virus
Li et al. Mouse mesenchymal stem cells from bone marrow differentiate into smooth muscle cells by induction of plaque-derived smooth muscle cells
Pewkliang et al. Immortalized hepatocyte-like cells: A competent hepatocyte model for studying clinical HCV isolate infection
CN100500836C (zh) Hcv病毒体外培养方法
Choi et al. MicroRNA-27a Modulates HCV Infection in Differentiated Hepatocyte-Like Cells from Adipose Tissue
Eugène Development of a representative 3D human model derived from iPSC to study hepatitis B virus in vitro
ISKANDAR The Potential Therapeutic Effect of Adult and Young Bone Marrow Derived-Mesenchymal Stem Cells on Hepatocellular Carcinoma in Rat Experimental Model
Meuleman et al. 861 THE LECTIN GRIFFITHSIN HAS ANTIVIRAL ACTIVITY AGAINST HEPATITIS C VIRUS IN VITRO AND IN VIVO

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180416

Address after: No. 139, Pu Qing Road, Rugao, Jiangsu

Applicant after: Weishi Pharmaceutical (Rugao) Co., Ltd.

Address before: British Virgin Islands toto

Applicant before: Pioneer drug development company limited

GR01 Patent grant
GR01 Patent grant